Trial Profile
Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms KEYNOTE-001
- Sponsors Merck Sharp & Dohme Corp.
- 11 Sep 2023 Result of pooled analysis from KEYNOTE-001,KEYNOTE-059, KEYNOTE-048, KEYNOTE-427, KEYNOTE-052, KEYNOTE-361 assessing Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression published in the Cancer Cell.
- 01 Oct 2022 Results (n=1194) of retrospective analysis of two studies(KEYNOTE-001 and KEYNOTE-059) assessing Lesion-to-lesion heterogeneity in response to pembrolizumab therapy presented at the CRI-ENCI-AACR 6th Annual International Cancer, Immunotherapy Conference
- 27 Sep 2022 Patients (n=27) from this study were used to evaluate circulating immune predictors of pembrolizumab efficacy in advanced NSCLC patients, published in the Clinical Cancer Research